Speclipse develops the Spectra-Scope®, a portable diagnostic device that utilizes Laser-Induced Plasma Spectroscopy (LIPS) and AI algorithms to rapidly analyze skin tissue for oncological conditions. This technology provides dermatologists with precise biochemical insights, enabling early detection of skin cancer and improving patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for diagnosing skin cancer, such as dermoscopy and biopsy, can be time-consuming, require specialized skills, and may result in scarring. This can lead to delays in diagnosis and treatment, as well as unnecessary invasive procedures.
Solution
Speclipse offers the Spectra-Scope®, a portable diagnostic device that utilizes Laser-Induced Plasma Spectroscopy (LIPS) and AI algorithms to provide rapid, scar-free analysis of skin tissue for oncological conditions. The device employs LIPS to detect the biochemical information of skin tissue, which is then analyzed by a deep-learning AI algorithm for fast and accurate diagnostics. This technology enables dermatologists to make immediate assessments of suspicious lesions at the point of care, potentially reducing the need for biopsies.
Target Audience
The primary target audience includes dermatologists and other medical professionals who require a rapid, non-invasive method for skin cancer diagnosis.
Features
- Portable, lightweight design for point-of-care use
- Laser-Induced Plasma Spectroscopy (LIPS) technology for biochemical analysis of skin tissue
- Deep-learning AI-based diagnostic algorithm for rapid and accurate oncological assessments
- Non-invasive procedure, eliminating the risk of scarring
- Real-time results, enabling immediate clinical decision-making